Trump calls for price cuts on prescription drugs within 60 days in letters to Eli Lilly, Pfizer, other drugmakers

Former President Trump has sent letters to over a dozen major drugmakers, including Eli Lilly and Pfizer, demanding they lower U.S. prescription drug costs within 60 days. The demands include implementing "most favored nation" pricing for Medicaid and new drugs, returning foreign revenues, and creating direct-to-consumer options, citing high U.S. drug prices. While this represents renewed political pressure on the pharmaceutical sector, experts question Trump's executive authority without congressional action, anticipating fierce industry pushback, and noting that past voluntary approaches have failed, contrasting with the Inflation Reduction Act's established Medicare negotiation mechanism.

Analysis

Former President Trump has escalated political pressure on the pharmaceutical sector by demanding that over a dozen major drugmakers, including Eli Lilly (LLY), Pfizer (PFE), and Merck (MRK), lower U.S. prescription drug prices within 60 days. The demands are substantial, calling for the application of a 'most favored nation' rule to align U.S. prices with lower international benchmarks for both Medicaid and all newly approved drugs. This directive represents a significant headline risk for the industry, reflected in the uniformly negative sentiment scores across all named tickers. However, the immediate financial impact is highly uncertain. Experts cited in the report express significant skepticism regarding the president's authority to enforce such measures unilaterally without congressional approval, noting that any attempt would likely face fierce legal and political resistance from the industry. This contrasts sharply with the established, legally-mandated Medicare drug price negotiations under the Inflation Reduction Act, which has a clear mechanism and is projected to yield $6 billion in savings by 2026. The non-committal initial responses from companies like Novo Nordisk and Eli Lilly underscore the current 'wait-and-see' approach, as the industry assesses the viability of this political threat.

Key Decisions for Investors

• Treat this development as a significant headline risk that elevates political uncertainty for the pharmaceutical sector, but recognize that the president's authority to enforce these demands without congressional action is highly questionable.
• It is crucial to distinguish between this speculative threat and the concrete, legislated pricing pressures from the Inflation Reduction Act's negotiation mechanism, which represents a more tangible and forecastable headwind.
• Monitor for a unified industry response via lobbying groups like PhRMA, as its legal and political strategy will be the primary determinant of whether these demands translate into actual financial impact for companies like Eli Lilly, Pfizer, and Merck.